BRPI0412127A - método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesma - Google Patents

método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesma

Info

Publication number
BRPI0412127A
BRPI0412127A BRPI0412127-9A BRPI0412127A BRPI0412127A BR PI0412127 A BRPI0412127 A BR PI0412127A BR PI0412127 A BRPI0412127 A BR PI0412127A BR PI0412127 A BRPI0412127 A BR PI0412127A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
treating
pharmaceutically acceptable
symptom
compound
Prior art date
Application number
BRPI0412127-9A
Other languages
English (en)
Inventor
Scott W Grimm
Helen R Winter
Patricia C Davis
Raymond F Suckow
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0412127A publication Critical patent/BRPI0412127A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODO DE TRATAR PELO MENOS UM SINTOMA OU CONDIçãO, USO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, E, USO DA MESMA". Um método de tratar ansiedade, agitação, hostilidade, pânico, distúrbios de comer, sintomas afetivos, sintomas do humor, sintomas negativos e positivos psicóticos, comumente associados com esquizofrenia, demência ansiedade, depressão, distúrbios do humor, distúrbios bipolares, mania bipolar, depressão bipolar, distúrbios cognitivos e distúrbios neurodegenerativos, compreendendo administrar uma quantidade eficaz da Fórmula (I) ou seu sal farmaceuticamente aceitável. Em outro aspecto da invenção, uma composição farmacêutica é provida, compreendendo uma quantidade eficaz da Fórmula (I) ou seu sal farmaceuticamente aceitável e pelo menos um veículo ou diluente farmaceuticamente aceitável.
BRPI0412127-9A 2003-07-02 2004-06-28 método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesma BRPI0412127A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48436503P 2003-07-02 2003-07-02
PCT/GB2004/002783 WO2005002586A1 (en) 2003-07-02 2004-06-28 Metabolite of quetiapine

Publications (1)

Publication Number Publication Date
BRPI0412127A true BRPI0412127A (pt) 2006-08-15

Family

ID=33563981

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412127-9A BRPI0412127A (pt) 2003-07-02 2004-06-28 método de tratar pelo menos um sintoma ou condição, uso de um composto, composição farmacêutica, e uso da mesma

Country Status (20)

Country Link
US (1) US20050026900A1 (pt)
EP (1) EP1644005B1 (pt)
JP (1) JP2007516193A (pt)
KR (1) KR20060082037A (pt)
CN (1) CN1816339B (pt)
AR (1) AR045004A1 (pt)
AT (1) ATE477803T1 (pt)
AU (1) AU2004253334A1 (pt)
BR (1) BRPI0412127A (pt)
CA (1) CA2531284A1 (pt)
DE (1) DE602004028739D1 (pt)
ES (1) ES2349091T3 (pt)
IL (1) IL172616A0 (pt)
IS (1) IS8283A (pt)
MX (1) MXPA05013869A (pt)
NO (1) NO20060556L (pt)
RU (1) RU2005141060A (pt)
TW (1) TW200509944A (pt)
UY (1) UY28400A1 (pt)
WO (1) WO2005002586A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4414237B2 (ja) * 2002-03-20 2010-02-10 テバ ファーマシューティカル インダストリーズ リミティド ケチアピンヘミフマレートの結晶形
BRPI0417749A (pt) 2003-12-22 2007-04-10 Acadia Pharm Inc composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
WO2008021463A2 (en) * 2006-08-15 2008-02-21 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
EP1838325A1 (en) * 2005-01-07 2007-10-03 AstraZeneca AB NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
US20060252744A1 (en) * 2005-04-04 2006-11-09 Burstein Ethan S Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
JP2008502707A (ja) * 2005-04-14 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド クエチアピンフマレートの調製方法
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
EP1951694A4 (en) * 2005-11-18 2010-09-22 Astrazeneca Ab FORMS OF SALTS
US8389510B2 (en) 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
WO2007062338A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Solid formulations
JP2009516708A (ja) * 2005-11-18 2009-04-23 アストラゼネカ・アクチエボラーグ 液体製剤
EP1951257A4 (en) * 2005-11-18 2008-11-05 Astrazeneca Ab CRYSTALLINE FORMS
WO2008118141A2 (en) * 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
JP2010514682A (ja) * 2006-12-20 2010-05-06 アストラゼネカ・アクチエボラーグ 化合物及びその使用
JP2010514684A (ja) * 2006-12-20 2010-05-06 アストラゼネカ・アクチエボラーグ 化合物及びその使用
CN101616661A (zh) * 2006-12-20 2009-12-30 阿斯利康(瑞典)有限公司 化合物及其用途
CN101641101A (zh) * 2007-03-22 2010-02-03 阿斯利康(瑞典)有限公司 治疗心境障碍的方法
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
RS58335B1 (sr) 2010-03-11 2019-03-29 Kempharm Inc Konjugati kvetiapina sa masnom kiselinom, proces za njihovo dobijanje i njihova primena
CN102552128B (zh) * 2012-02-28 2013-09-18 陆荣政 一种富马酸喹硫平注射液及其制备方法
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
GB1192812A (en) * 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3966949A (en) * 1973-10-12 1976-06-29 Richardson-Merrell Inc. Pharmaceutical compositions and preparing same
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5750566A (en) * 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
US6342488B1 (en) * 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
WO2004064753A2 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease

Also Published As

Publication number Publication date
ATE477803T1 (de) 2010-09-15
US20050026900A1 (en) 2005-02-03
WO2005002586A1 (en) 2005-01-13
RU2005141060A (ru) 2006-07-27
IS8283A (is) 2006-02-01
CN1816339B (zh) 2010-12-15
UY28400A1 (es) 2005-01-31
KR20060082037A (ko) 2006-07-14
EP1644005B1 (en) 2010-08-18
EP1644005A1 (en) 2006-04-12
ES2349091T3 (es) 2010-12-27
AR045004A1 (es) 2005-10-12
JP2007516193A (ja) 2007-06-21
NO20060556L (no) 2006-04-03
CN1816339A (zh) 2006-08-09
TW200509944A (en) 2005-03-16
AU2004253334A1 (en) 2005-01-13
MXPA05013869A (es) 2006-02-28
DE602004028739D1 (de) 2010-09-30
CA2531284A1 (en) 2005-01-13
WO2005002586A8 (en) 2006-02-09
IL172616A0 (en) 2006-04-10

Similar Documents

Publication Publication Date Title
MXPA05013869A (es) Metabolito de quetiapina.
KR950700060A (ko) 운동 뉴우런 질병의 치료에 유용한 약품을 얻기 위한 2-아미노-6-트리플루오로메톡시 벤조티아졸(리루졸)의 사용(Application of 2-amino 6-trifluoromethoxy benzothiazole(riluzole) for obtaining a drug useful in the treatment of motor neuron diseases)
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
PT1404324E (pt) Formas de dosagem administradas oralmente de pró-fármacos análogas de gaba tendo toxicidade reduzida
CY1111047T1 (el) Θεραπεια οφθαλμικων νεοαγγειακων διαταραχων οπως κηλιδωδους εκφυλισμου, αγγειοειδων γραμμωσεων, ραγοειδιτιδας και οιδηματος της ωχρης κηλιδας
CY1111206T1 (el) Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
BR0113666A (pt) Inibidores da protease peptidomimética
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
BR0109161A (pt) Beta-carbolinas substituìdas com atividade de inibição de ikb-quinase
BR9807132A (pt) Derivados de pirrolidina tendo atividade inibitória de fosfolipase a2
ATE305917T1 (de) Difluormethylen aromatische ether und ihre verwendung als inhibitoren des glycin-typ-1- transporters
BRPI0313286A2 (pt) Composição e atividade antiviral de derivados de piperazina azaindoloxoacético substituìda
BR0212031A (pt) Preparados de combinação de derivados de 1,1-dióxido de 1-4-benzotiepina com outras substâncias ativas e seu emprego
JP2007516193A5 (pt)
KR920016088A (ko) 하부 요로 질환의 치료
TWI340639B (en) Pharmaceutical composition for treating luts, other than urinary incontinence, associated with oab and/or bph
EE200100478A (et) Vahend artriitilise haiguse raviks
ATE295183T1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
EP1666064A4 (en) MEANS FOR THE TREATMENT OF DISEASES RELATED TO IMMUNOGLOBULIN GEN TRANSLATION
Kopala et al. The use of risperidone in severely demented patients with persistent vocalizations
SE9902935D0 (sv) Pharmaceutical compositions
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
BR9910185A (pt) Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana
TW200507854A (en) Metabolite

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.